Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: Cancer Res. 2017 Aug 15;77(19):5228–5235. doi: 10.1158/0008-5472.CAN-17-0320

Figure 1.

Figure 1

A. TALEN engineering strategy. tAR-2 TALENs were designed to cut AR (red arrows) and delete the 22Rv1 duplication. B. An mCherry/split GFP reporter harboring a tAR-2 cut site (CS) was used to identify, sort, and plate transfected cells with tAR-2 activity C. Cells were cultured in steroid-deplete medium and treated with 1 nM dihydrotestosterone (DHT), 10 μM enzalutamide (Enza), or vehicle control as indicated. Blots were probed with antibodies specific for AR (N20), AR-V7, or ERK2 (loading control). D. Growth of cells transfected with indicated siRNAs was assessed by crystal violet staining. Bars represent mean fold growth on Day 6 relative to Day 0 (n = 12, error bars = 95% confidence intervals). **** p≤0.0001, ** p ≤ 0.01, ns p>0.05, Mann Whitney U tests. Bottom panels illustrate western blots of lysates from transfected cells, probed with antibodies as in C.